CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) CEO Samarth Kulkarni sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $60.51, for a total value of $3,025,500.00. Following the completion of the sale, the chief executive officer now owns […]
CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) traded up 5.8% during mid-day trading on Monday . The stock traded as high as $64.61 and last traded at $64.57. 1,325,700 shares traded hands during mid-day trading, a decline of 34% from the average session volume of 2,021,186 shares. The stock had previously closed at $61.01. […]
CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) – Stock analysts at Leerink Partnrs upped their Q4 2023 EPS estimates for shares of CRISPR Therapeutics in a research note issued to investors on Tuesday, January 23rd. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings per share of $0.33 for the quarter, […]
CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) – Investment analysts at Leerink Partnrs upped their FY2023 EPS estimates for CRISPR Therapeutics in a note issued to investors on Tuesday, January 23rd. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($2.73) per share for the year, up from their prior forecast of […]
CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) saw a significant drop in short interest in December. As of December 31st, there was short interest totalling 16,250,000 shares, a drop of 6.2% from the December 15th total of 17,330,000 shares. Based on an average daily trading volume, of 2,750,000 shares, the short-interest ratio is presently […]